Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
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
cJ7WkrcfF4NHsg1V
